Thus, dictamnine inhibits the ACAT1 and FABP-1expression and activates ACSL4 expression, which collectively contributes to lipid metabolism disorder and the progression of hepatotoxicity. This evidence concerns the gene ACAT1 and Disorder of lipid metabolism.